Sat, Aug 23, 2014, 10:01 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Nov 19, 2012 1:36 PM Flag

    Genzyme-Isis Cholesterol Drug + BIOGEN -ISIS receive up to an additional $259 million in a licensing fee

    Isis stands to claim $25 million milestone if U.S. regulator approves new drug.
    Crooke is also waiting to hear from regulators in Europe by the end of this year gives another $47million milestone payment. Both has option to get royalties to get another 5 Years.

    •Isis formed a new strategic alliance with Biogen Idec to develop and commercialize a drug to treat DM1 that expands Isis' severe and rare disease franchise. Isis received a $12 million upfront payment and is eligible to receive up to an additional $259 million in a licensing fee and milestone payments. Isis will also receive double-digit royalties on product sales.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ISIS
34.33+0.16(+0.47%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.